Company
Headquarters: Victoria, BC, Canada
Employees: 294
CEO: Mr. Peter S. Greenleaf M.B.A.
C$2.15 Billion
CAD as of July 1, 2021
US$1.74 Billion
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | June 30, 2021 |
Revenue TTM | C$51.0 M |
EBITDA | C$-126,012,000 |
Gross Profit TTM | C$-209,000 |
Profit Margin | -249.26% |
Operating Margin | -250.53% |
Quarterly Revenue Growth | 2946.70% |
Aurinia Pharmaceuticals Inc. has the following listings and related stock indices.
Stock: TSX: AUP wb_incandescent
Stock: NASDAQ: AUPH wb_incandescent
Stock: FSX: IKAP wb_incandescent